Pharma-Biotech Product & Company Valuation
Course - Switzerland
By attending this course, you will:
1 Know what determines the value of life science biotechs and emerging pharma companies. 2 Gain a thorough understanding of key valuation terms, concepts, tools & techniques. 3 Learn and practice how to: Use a model that assesses the soft factors of a biotech company prior to its valuation. Calculate the value of a biotech company. Calculate the value of a development compound with an excel tool you can take home and use for any other pharmaceutical product in development. Structure licensing deals between pharma and biotech, covering issues such as milestones and royalty payments. 4 Gain expert insight and advice from Patrik Frei and Johan Ohlsson who have assessed and valued numerous products and companies in the life sciences industry.
An Introductory Course: Dr. Patrik Frei
Europe’s top valuation expert of high-growth life science companies.
Patrik is Founder & CEO of Venture Valuation AG, specialists in independent assessments and valuation of emerging high-growth companies in biotechnology and life sciences.
Patrik and his team carried out all external valuations for the Novartis Venture Fund.
![patrik frei color[1]](http://cdn2.hubspot.net/hub/45279/file-14325332-jpg/images/patrik_frei_color[1].jpg)
(Courtesy of http://www.celforpharma.com/pharma-management/training/pharma-product-company-valuation-course.html)
Wed, Oct 24, 2012 - Wed, Oct 24, 2012
Hilton Zurich Airport Hotel
Zurich, Switzerland
If you'd like to ask a question or post a comment about this talk please do so below.
This seminar posting is brought to you by Biotechnology Calendar, Inc. providing access to research information and research tools for nearly 20 years. Visit our Science Market Update Blog for current science funding and market information or see our schedule of upcoming science research laboratory product shows.
